Cybin

149 articles about Cybin

• Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

  11/3/2022

  Cybin Inc. is pleased to announce its participation in the following upcoming investor events.

• Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit

  11/1/2022

  Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit.

• Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds

  9/27/2022

  Cybin Inc. has entered into an agreement with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules from Mindset (the “Agreement”).

• Mindset Pharma Provides Strategic Intellectual Property License to Cybin

  9/27/2022

  Mindset Pharma Inc. today announced an exclusive licensing agreement for Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) to acquire intellectual property rights for a subset of Mindset’s preclinical compounds (the “Agreement”).

• Cybin to Participate in Upcoming Scientific and Investor Conferences

  9/21/2022

  Cybin Inc. is pleased to announce its participation in the following upcoming conferences.

• Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

  9/20/2022

  Cybin Inc. announced that it has successfully achieved its research and development milestones that helped to build and progress its innovative pipeline of investigational psychedelic therapeutics ahead of projected timelines.

• Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

  8/30/2022

  Cybin Inc. is pleased to announce that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder.

• Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  8/25/2022

  Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference.

• Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial

  8/17/2022

  Cybin Inc. and Clinilabs Drug Development Corporation today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog that is being developed for the treatment of major depressive disorder (“MDD”).

• Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights

  8/8/2022

  Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today reported unaudited financial results for its first quarter ended June 30, 2022 and recent business highlights.

• Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference

  7/28/2022

  Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference.

• Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

  7/11/2022

  Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a Phase 1 N,N-dimethyltryptamine (“DMT”) study (the “Acquisition”) from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”).

• Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

  6/27/2022

  Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder.

• Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

  6/22/2022

  Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today reported audited financial results for its fiscal year ended March 31, 2022 and recent business highlights.

• Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

  6/16/2022

  Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022.

• Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

  6/9/2022

  Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has received Institutional Review Board (“IRB”) approval to begin the first-in-human Phase 1/2a clinical trial evaluating CYB003, its proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”).

• Cybin Acquires DMT Clinical Study from Entheon Biomedical

  6/7/2022

  Acquisition of largest Phase 1 DMT study conducted to date is expected to accelerate CYB004 program timeline by nine months.

• Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program

  6/3/2022

  Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced the team of 28 esteemed faculty and advisors who will lead the Company’s EMBARK Psychedelic Facilitator Training Program.

• Cybin to Host Key Opinion Leader Webinar on June 9, 2022

  6/2/2022

  Featured speakers include Dr. John Krystal, Yale School of Medicine, and Dr. David Nutt, Imperial College London.

• Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder

  5/31/2022

  Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, is pleased to announce the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration for its Phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”).